DCVax-l for rGBM will* be a therapy unto its own. It follows recurrence. Regardless of whether it was preceded by Temodar (control group in trial) DCVax-l with Temidar, or something else.
Once approved for rGBM, manufacture of L from r GBM tumor material is a given and rGBM and new GBM material can be stored properly before the possibility of approval or for other trial considerations. A backlog of stored tumor tissue is likely building even now. Best wishes.
Market Data 
Markets 
AI
